이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

LianBio 관리

관리 기준 확인 2/4

LianBio's CEO는 Adam Stone, Dec2023 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 5.54K 가치에 해당하는 회사 주식의 0.016% 직접 소유합니다. 5.54K. 경영진과 이사회의 평균 재임 기간은 각각 0.7 년과 2.8 년입니다.

주요 정보

Adam Stone

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.02%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

CEO

Adam Stone (44 yo)

less than a year

테뉴어

US$62,073

보상

Mr. Adam Leo Stone is Chief Investment Officer & Head of Research of Perceptive Advisors LLC. He joined the Perceptive Advisors LLC in 2006. He serves as CEO & Director at Perceptive Capital Solutions Corp...

리더십 팀

이름	위치	테뉴어	보상	소유권
Konstantin Poukalov	Founder & Executive Chairman	5yrs	US$62.07k	0.016% $ 5.0k
Adam Stone	Interim CEO & Director	less than a year	US$62.07k	0.016% $ 5.0k
Ehong Gu	Interim CFO	less than a year	데이터 없음	0% $ 0
Ji Chen	Senior VP & General Counsel	no data	데이터 없음	데이터 없음
Brianne Jahn	Chief Business Officer	3.1yrs	US$2.69m	데이터 없음
Levvy Lv Eng	Senior VP & Global Head of Development	no data	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

40yo

평균 연령

경험이 풍부한 관리: LIAN.Y 의 관리팀은 경험 (평균 재직 기간 0.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Konstantin Poukalov	Founder & Executive Chairman	5yrs	US$62.07k	0.016% $ 5.0k
Adam Stone	Interim CEO & Director	5yrs	US$62.07k	0.016% $ 5.0k
Tassos Anastasios Gianakakos	Independent Director	4.2yrs	US$128.07k	0.34% $ 105.8k
Susan Silbermann	Independent Director	3yrs	US$121.44k	0.016% $ 5.0k
Neil Kumar	Director	5yrs	데이터 없음	0% $ 0
Elliott Levy	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Mathias Hukkelhoven	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Wei Chen	Independent Director	2.5yrs	US$285.89k	0% $ 0
Zhao Yan	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 이사회: LIAN.Y 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

LianBio 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Less than half of directors are independent

Recent updates

LianBio(OTCPK:LIAN.Y) dropped from NASDAQ Composite Index

With No Cure In Sight, Drugs Firm LianBio Begins Exit Strategy

LianBio Intends to File Form 25 with SEC

LianBio Announces Chief Financial Officer Changes

LianBio Announces Chief Financial Officer Changes

Lianbio Announces Chief Executive Officer Changes

Concentra Biosciences, LLC cancelled the acquisition of LianBio (NasdaqGM:LIAN) from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others.

LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

New major risk - Revenue and earnings growth

LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023

Price target decreased by 19% to US$6.24

Forecast to breakeven in 2023

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans

Lianbio Announces Marketing Approval of CAMZYOS®? (Mavacamten) in Singapore

LianBio Announces Marketing Approval of CAMZYOS(R) (mavacamten) in the Macau Special Administrative Region (SAR) of China

We're Hopeful That LianBio (NASDAQ:LIAN) Will Use Its Cash Wisely

Price target decreased to US$8.23

We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth

LianBio Announces the Resignation of Debra Yu, M.D. as President and Chief Strategy Officer, Effective January 1, 2023

Less than half of directors are independent

Price target increased to US$12.00

LianBio Doses First Patient in Phase 1 Trial of BBP-398 in Chinese Patients with Advanced Solid Tumors

LianBio Doses First Patient in Registrational Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

Companies Like LianBio (NASDAQ:LIAN) Are In A Position To Invest In Growth

Lianbio Completes Enrollment in Pivotal Phase 3 EXPLORER-CNTrial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients

Will LianBio (NASDAQ:LIAN) Spend Its Cash Wisely?

LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers

U.S. Food and Drug Administration Approves Camzyos (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Less than half of directors are independent

LianBio Announces Formation of Scientific Advisory Board

LianBio Appoints Wei Wei Chen to Board of Directors

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

Here's Why LianBio (NASDAQ:LIAN) Must Use Its Cash Wisely

Lianbio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

LianBio Announces Approval of Infigratinib Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

No independent directors

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령